Before We Start
One altered target protein, resistance to an entire drug class
MRSA's resistance doesn't come from destroying the antibiotic or pumping it back out — it comes from having a version of the drug's own target protein that the drug simply can't bind well. Understanding that mechanism explains why the resistance is so broad.
💡 Memory Trick
S. aureus: catalase+, coagulase+. "MRSA" = Methicillin-Resistant S. aureus — altered PBP2a. The altered protein still does its normal job building the cell wall; it just can't be blocked by beta-lactams anymore.
The Key Points
Identification, key toxins, the resistance mechanism, and treatment
S
S. aureus identification — catalase-positive, coagulase-positive
Staphylococcus aureus is catalase-positive, distinguishing it from Streptococcus, and coagulase-positive, distinguishing it from coagulase-negative staph species (CoNS), which are generally far less pathogenic. S. aureus also characteristically forms golden colonies on blood agar.
🦠 A lab technician uses the coagulase test specifically to distinguish S. aureus from other, less pathogenic coagulase-negative staph species growing on the same culture plate.
T
Key toxins — TSST-1, exfoliatin, PVL
S. aureus produces several clinically important toxins: TSST-1, causing toxic shock syndrome; exfoliatin, causing scalded skin syndrome; and PVL, causing necrotizing pneumonia — each toxin producing a genuinely distinct clinical syndrome.
🦠 A patient with widespread skin peeling and blistering is diagnosed with staphylococcal scalded skin syndrome, caused specifically by the exfoliatin toxin.
M
MRSA — the mecA gene and PBP2a
MRSA (Methicillin-Resistant Staphylococcus aureus) carries the mecA gene, which encodes an altered penicillin-binding protein called PBP2a. This altered protein has low affinity for beta-lactam antibiotics, meaning it can continue building the cell wall even in the drug's presence — making MRSA resistant to ALL penicillins and cephalosporins, not just methicillin specifically.
🦠 A beta-lactam antibiotic fails to treat an MRSA infection because PBP2a, the altered target protein encoded by mecA, simply doesn't bind these drugs effectively, allowing cell wall synthesis to continue regardless.
R
Treating MRSA — vancomycin, daptomycin, linezolid
Because MRSA is resistant to all beta-lactams, treatment requires alternative antibiotics that work through genuinely different mechanisms unaffected by the PBP2a resistance: vancomycin, daptomycin, or linezolid.
🦠 A patient with a confirmed MRSA infection is switched to vancomycin, since standard beta-lactam antibiotics would be completely ineffective against this resistant strain.
🏥 Applied Scenario
A patient's Staph infection fails to respond to a standard beta-lactam antibiotic, and further testing confirms the strain carries the mecA gene.
Step 1
Identify what mecA actually confers: What does the mecA gene specifically confer? Production of PBP2a, an altered penicillin-binding protein with low affinity for beta-lactam antibiotics — this is exactly what defines MRSA and explains the treatment failure observed.
Step 2
Recognize the scope of resistance: Because PBP2a confers resistance to ALL penicillins and cephalosporins — not just methicillin specifically, despite the name — the patient needs to be switched to an entirely different antibiotic class, not just a different beta-lactam.
Step 3
Select an appropriate alternative: The physician switches to vancomycin, one of the standard alternative treatments for MRSA, since it works through a mechanism entirely unaffected by the PBP2a resistance mutation.
Step 4
Conclusion: A resistance gene's name (mecA, "methicillin" resistance) can understate how broad the actual resistance is — PBP2a's low affinity applies across the whole beta-lactam class, not just the drug in the gene's name.
📌 Exam Application
Exams test whether you know the identification tests for S. aureus (catalase-positive, coagulase-positive), the key toxins and their associated syndromes (TSST-1/toxic shock, exfoliatin/scalded skin, PVL/necrotizing pneumonia), and specifically the mecA/PBP2a mechanism behind MRSA resistance, along with appropriate alternative treatments.
⚠️ The Trap — Assuming MRSA Is Only Resistant to Methicillin Specifically
The most common trap is assuming MRSA is only resistant to methicillin specifically, based on the name. In reality, the mecA gene's PBP2a product confers resistance to ALL penicillins and cephalosporins broadly, not just methicillin — the name is a historical artifact from when methicillin was the specific drug first used to identify this resistance pattern, back when it was introduced to treat penicillin-resistant S. aureus.
✓ Quick Self-Test
Answer before checking:
1. What two lab tests confirm S. aureus identification?
2. What syndrome does the TSST-1 toxin cause?
3. What syndrome does the exfoliatin toxin cause?
4. What does the mecA gene encode, and what effect does it have?
5. Name two antibiotics used to treat MRSA.
Answers:
1. Catalase-positive and coagulase-positive.
2. Toxic shock syndrome.
3. Staphylococcal scalded skin syndrome.
4. PBP2a, an altered penicillin-binding protein with low affinity for beta-lactams, conferring resistance to all penicillins and cephalosporins.
5. Vancomycin, daptomycin, or linezolid (any two).